Wealth Enhancement Advisory Services LLC Sells 157,309 Shares of Zoetis Inc. (NYSE:ZTS)

Wealth Enhancement Advisory Services LLC lowered its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 51.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 148,302 shares of the company's stock after selling 157,309 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Zoetis were worth $24,418,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Schroder Investment Management Group lifted its stake in Zoetis by 2.6% in the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company's stock worth $40,036,000 after purchasing an additional 6,169 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Zoetis by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after buying an additional 120,158 shares in the last quarter. Portside Wealth Group LLC raised its position in shares of Zoetis by 24.7% during the 1st quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock valued at $5,550,000 after buying an additional 6,672 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in shares of Zoetis by 72.4% during the 4th quarter. Oppenheimer & Co. Inc. now owns 93,114 shares of the company's stock valued at $15,171,000 after buying an additional 39,114 shares in the last quarter. Finally, OFI Invest Asset Management purchased a new stake in shares of Zoetis during the 4th quarter valued at about $37,298,000. Institutional investors own 92.80% of the company's stock.

Zoetis Trading Up 1.4%

NYSE ZTS opened at $157.26 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. The company has a fifty day simple moving average of $159.58 and a two-hundred day simple moving average of $163.31. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The stock has a market cap of $70.01 billion, a P/E ratio of 28.23, a P/E/G ratio of 2.61 and a beta of 0.94.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same quarter last year, the company posted $1.38 earnings per share. The firm's revenue was up 1.4% compared to the same quarter last year. On average, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be given a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.27%. Zoetis's dividend payout ratio is presently 35.91%.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. UBS Group decreased their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and cut their price target for the company from $165.00 to $160.00 in a report on Wednesday. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. Finally, Piper Sandler upped their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $212.13.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the sale, the executive vice president now owns 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.18% of the stock is owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.